Fact-checked by Grok 2 weeks ago

Vesicoureteral reflux

Vesicoureteral reflux (VUR), also known as vesicoureteric reflux, is a common urologic condition in which abnormally flows backward from the into the and sometimes up to the , rather than being expelled during . This flow disrupts the normal one-way mechanism at the ureterovesical , potentially leading to recurrent urinary tract infections (UTIs) and kidney damage if untreated. VUR is classified into five based on severity, from 1 (mild, involving only the ) to 5 (severe, with ureter dilation, tortuosity, and kidney blunting). It primarily affects infants and young children, with an estimated of 1% to 2% in the general pediatric , though up to one-third of children with febrile UTIs are found to have VUR. The condition arises from two main forms: primary VUR, which is congenital and results from an immature or defective ureteral valve that fails to prevent backflow, often resolving spontaneously as the child grows and the ureters lengthen; and secondary VUR, caused by acquired factors such as bladder outlet obstruction, (e.g., from ), or high bladder pressure from conditions like posterior urethral valves in boys. Risk factors include a family history (affecting more than one in four siblings or one in three offspring of affected parents), female sex (particularly after infancy), and age under 2 years. Many cases are asymptomatic and detected incidentally via prenatal showing or during evaluation for UTIs, but symptoms when present may include fever, painful urination, frequent or urgent urination, , bed-wetting beyond typical age, and poor in infants. Diagnosis typically involves renal and bladder ultrasound to assess for dilation or scarring, followed by a voiding cystourethrogram (VCUG) to visualize during and assign a grade, along with and culture to rule out . focuses on preventing complications like renal scarring, which can lead to or ; low-grade VUR (grades 1–3) often resolves without intervention within 5 years in up to 80% of cases, while higher grades may require continuous low-dose antibiotics to prevent UTIs, endoscopic injections of bulking agents to strengthen the valve, or surgical ureteral reimplantation for persistent severe . Early detection and treatment are crucial, as untreated VUR increases the risk of and long-term renal impairment.

Overview

Definition

Vesicoureteral reflux (VUR) is defined as the abnormal retrograde flow of urine from the bladder into the ureters and potentially the kidneys, resulting from incompetence at the vesicoureteral junction. This condition disrupts the normal unidirectional flow of urine during voiding, allowing backflow that can lead to stasis in the upper urinary tract. The ureterovesical junction (UVJ) serves as the primary anti-reflux mechanism in the urinary system, featuring an oblique insertion of the ureter into the bladder wall, a sufficient length of the intravesical submucosal tunnel, and muscular support from the detrusor muscle that compresses the ureter during bladder contraction. Incompetence here, often due to a shortened or absent tunnel, impairs the passive flap-valve action that prevents reflux under normal intravesical pressures. VUR can manifest as unilateral, affecting a single ureter, or bilateral, involving both ureters, with the latter more commonly associated with certain underlying anomalies. As a prevalent congenital , VUR affects approximately 1-2% of children, particularly in pediatric populations, and is a significant for recurrent urinary tract infections (UTIs) due to bacterial ascension into the kidneys. Untreated, it can contribute to renal scarring and long-term damage, including and , underscoring its importance in early detection and management.

Pathophysiology

Vesicoureteral reflux (VUR) occurs when the normal antireflux mechanism at the ureterovesical junction (UVJ) fails, allowing flow of from the into the and potentially the kidneys during voiding or increased intravesical pressure. In primary cases, this incompetence stems from an abnormally short intramural ureteral segment, which reduces the length-to-diameter ratio (typically less than 5:1) and impairs the flap-valve mechanism that compresses the ureter against the wall. Additionally, aperistaltic distal ureteral segments contribute by failing to generate adequate peristaltic waves to propel unidirectionally, further compromising UVJ function. The hydrodynamic basis of VUR involves transmission of elevated intravesical pressure—often exceeding 35 mm Hg during voiding—to the upper urinary tract, overcoming residual UVJ resistance and driving retrograde. This reflux promotes in the ureters and , creating an environment conducive to bacterial proliferation and ascension, which heightens the risk of . In secondary VUR, associated bladder dysfunctions such as detrusor-sphincter generate abnormally high voiding pressures, exacerbating pressure transmission and reflux without inherent UVJ anomalies. At the renal level, severe reflux enables intrarenal reflux, where enters the collecting ducts through compound (flat or concave) papillae, which are more permeable than simple papillae. This can lead to papillary damage from direct bacterial invasion and inflammatory mediators, with high pressures potentially causing forniceal rupture and perirenal urine extravasation. The resulting inflammatory response triggers through release of oxygen free radicals and proteolytic enzymes, initiating scarring in the renal .

Etiology

Primary Vesicoureteral Reflux

Primary vesicoureteral reflux (VUR) originates from congenital developmental anomalies at the (UVJ), where the ureter fails to insert properly into the during embryogenesis. The ureteric bud, which forms the , arises from the Wolffian duct around the fifth week of and must migrate cranially for correct positioning. Abnormal budding too caudal along the Wolffian duct results in an ectopic ureteral orifice, typically lateral and superior to the normal site, leading to a shortened intramural ureteral tunnel that inadequately supports the antireflux mechanism. This anatomical defect manifests as a reduced tunnel length-to-ureter ratio, normally approximately 5:1, which correlates directly with VUR severity grading; milder grades (I-II) feature relatively longer s that may improve with , while higher grades (IV-V) have more pronounced shortening and incompetence. Unlike secondary VUR, primary forms involve no underlying dysfunction or obstruction, relying solely on these intrinsic UVJ variants for occurrence. The short contributes to retrograde urine flow during contraction, as explored in the section. Genetic influences play a key role in primary VUR , with familial clustering evident in 27-51% of siblings of affected children, indicating a 30-50% recurrence risk. Mutations in genes like ROBO2, which regulates ureteric bud outgrowth and guidance, are identified in 3-5% of familial cases and disrupt normal UVJ formation. Additionally, primary VUR associates with syndromes such as VACTERL, occurring in up to 40% of patients due to related congenital anomalies. In neonates, primary VUR affects about 1% overall but up to 15-16% of those with prenatal detected via third-trimester , often prompting postnatal evaluation. Low-grade cases (I-II) exhibit high spontaneous resolution rates of 70-80% by age 5 and up to 80% by , attributed to progressive ureteral elongation and tunnel maturation without intervention.

Secondary Vesicoureteral Reflux

Secondary vesicoureteral reflux (VUR) is an acquired condition characterized by the retrograde flow of from the into the ureters and kidneys, resulting from elevated intravesical pressures due to underlying urinary tract obstructions or dysfunctions, rather than inherent defects in the ureterovesical . This contrasts with primary VUR, which stems from congenital anomalies, as secondary VUR often arises from treatable or reversible factors that overwhelm the normal antireflux mechanism at the ureterovesical . Anatomical causes of secondary VUR primarily involve obstructions that generate high bladder pressures, such as posterior urethral valves (PUV) in boys, which are obstructive membranes in the leading to bladder outlet obstruction and bilateral reflux. Ureteroceles, cystic dilatations of the distal ureter, can also obstruct urine flow and contribute to reflux, while extrinsic compression from tumors or other masses may similarly elevate pressures within the urinary tract. These anatomical issues disrupt normal voiding dynamics, forcing urine backward during bladder contraction. Functional causes include neurogenic bladder, often associated with conditions like or spinal dysraphism, where impaired neural control leads to detrusor overactivity and incomplete emptying, increasing outlet resistance and promoting reflux. Dysfunctional voiding, characterized by abnormal coordination of and muscles, and iatrogenic factors such as post-surgical complications (e.g., after or urethral procedures), can similarly result in high-pressure voiding and secondary VUR. In these scenarios, the underlying dysfunction drives persistent high pressures that exceed the protective of the ureterovesical junction. Secondary VUR typically presents later in childhood or adulthood, often triggered by the progression of the underlying , unlike the congenital onset of primary VUR. It has lower rates of spontaneous resolution—approximately 31% in cases with associated or bowel dysfunction compared to 61% without—necessitating interventions targeted at the root cause, such as relieving obstructions or managing neurogenic issues, to mitigate ongoing reflux. Associated conditions like , involving abdominal wall deficiency and urinary tract dilation, further exemplify how underlying pathologies drive secondary VUR through chronic high bladder pressures and impaired drainage. In spinal dysraphism, the neural tube defects lead to , emphasizing the role of the primary condition in perpetuating reflux.

Clinical Features

Signs and Symptoms

Vesicoureteral reflux (VUR) is frequently , particularly in cases of low-grade reflux, where it may remain undetected until incidentally identified through imaging studies performed for other reasons, such as evaluation of urinary tract infections (UTIs) or prenatal findings revealing . When symptoms occur, they are typically secondary to associated UTIs resulting from urine stasis, and may include recurrent febrile UTIs, , abdominal or flank pain, foul-smelling or cloudy urine, and voiding dysfunction such as urgency or incontinence. In infants, additional features can involve , poor feeding, fussiness, or vomiting, while older children might experience or daytime wetting after . Age-specific manifestations vary, with neonatal cases often presenting as prenatal without overt symptoms postnatally. In infants under 2 years, febrile UTIs are common, particularly in uncircumcised males, and may lead to poor growth or weight gain issues. School-age children, especially girls, are prone to breakthrough UTIs despite prophylaxis, alongside symptoms like or bowel control problems that exacerbate voiding issues. VUR is rare in adults unless secondary to other conditions, typically presenting with similar UTI-related symptoms. Screening for VUR is often prompted by a family history, as siblings of affected children have approximately a 27% and children of affected parents about a 33% , leading to targeted evaluation even in asymptomatic individuals. There are no unique physical examination findings specific to VUR; presentation relies on history of recurrent infections or related symptoms.

Complications

Vesicoureteral reflux (VUR) predisposes individuals, particularly children, to recurrent urinary tract infections (UTIs), including , which can escalate to if untreated. High-grade VUR combined with recurrent significantly heightens the risk of renal scarring, with studies identifying delayed treatment as a key exacerbating factor. In children, the presence of VUR during a UTI increases the risk of due to bacterial ascent into the kidneys. The primary renal complication of VUR is reflux nephropathy, characterized by cortical scarring from repeated episodes of , leading to (FSGS) through glomerular hypertrophy and . This scarring can progress to (CKD) and, in severe cases, end-stage renal disease (ESRD), particularly with bilateral involvement or high-grade reflux. Untreated VUR is associated with an increased risk of CKD, as evidenced by longitudinal studies linking early renal parenchymal damage to long-term functional decline. Systemic effects of VUR-related renal damage include , often driven by activation of the renin-angiotensin system in scarred kidneys, and resulting from glomerular injury. In adults with reflux nephropathy, prevalence ranges from 38% to 60%, contributing to further cardiovascular and renal morbidity. Bilateral renal involvement heightens the risk of complete renal failure, while serves as a poor prognostic indicator in affected patients. Long-term risks in children with VUR include growth impairment linked to renal scarring and recurrent infections, with studies showing significant associations between scarred kidneys and delayed somatic development. In females with scarred kidneys from VUR, overall complications occur in approximately 39% of cases, with reported in about 10%, underscoring the need for preconception renal evaluation.

Diagnosis

Diagnostic Methods

Diagnosis of vesicoureteral reflux (VUR) typically begins with laboratory evaluation to identify associated urinary tract infections (UTIs) and assess renal function, followed by imaging studies to detect structural abnormalities and confirm reflux. and urine culture are essential for detecting and confirming concurrent UTIs, which often prompt further investigation in children. Baseline creatinine is recommended to estimate and monitor for renal impairment, though no specific biomarkers exist for VUR itself. Renal and bladder serves as the initial non-invasive imaging modality, screening for , ureteral dilatation, and renal scarring, particularly in infants and young children. It is recommended within 24 hours of a febrile UTI in infants or for follow-up of prenatal , with postnatal imaging delayed until after the first week to avoid transient findings. While identifies upper tract abnormalities in about 15% of cases, its sensitivity for high-grade VUR is limited at approximately 59%, making it unsuitable as a standalone diagnostic tool. A technetium-99m-labeled dimercaptosuccinic acid ( is used to evaluate renal parenchymal scarring and cortical defects, often performed 6 months after a febrile UTI to assess for pyelonephritis-related damage. It is indicated when shows abnormalities, in cases of UTIs, or for grades III-V VUR, with a sensitivity of 75% for detecting reflux-related changes but lower specificity at 48%. Due to , its use has decreased in recent guidelines, prioritizing it for high-risk scenarios. The voiding cystourethrogram (VCUG) remains the gold standard for confirming VUR, visualizing reflux into the ureters and during bladder filling and voiding under , while also allowing grading of severity. Performed with diluted contrast at body temperature and low-pressure filling, it is indicated after a first febrile UTI if reveals , scarring, or other anomalies, or routinely after a second UTI in children aged 2-24 months. Contrast-enhanced voiding urosonography (ceVUS) offers a using contrast agents, providing comparable for VUR detection and grading, particularly recommended in European guidelines for initial evaluation or follow-up to minimize . cystography offers an with substantially lower (about 10% of VCUG), suitable for follow-up screening in high-grade cases, though it provides less anatomical detail. Indications for diagnostic evaluation include febrile UTIs in children under 2 years, familial screening in siblings with a history of VUR or renal abnormalities, and follow-up of prenatal . Guidelines from the 2010s and 2020s, such as those from the (reaffirmed 2016) and American Urological Association (2017), emphasize a risk-based approach to reduce unnecessary VCUGs, limiting routine imaging after an initial UTI unless abnormalities are present. The European Association of Urology's paediatric guidelines similarly advocate selective use based on clinical factors like recurrent infections or congenital anomalies.

Severity Grading

Vesicoureteral reflux (VUR) is classified using the International Reflux Study grading , a standardized radiographic developed to assess severity based on voiding cystourethrogram (VCUG) findings. This categorizes VUR into five grades, from I (mild) to V (severe), focusing on the extent of , ureteral , and calyceal involvement. The grading provides visual and anatomical criteria to ensure consistency in evaluation across clinical settings. The grades are defined as follows:
GradeDescription
IReflux limited to the distal without involving the or calyces. No or .
IIReflux extends to the and calyces, but without , blunting, or of the or collecting system.
IIIReflux into the and calyces with mild to moderate and of the , and mild to moderate of the and calyces, but no or slight blunting of the fornices.
IVReflux into the and calyces with moderate to gross and of the , moderate of the and calyces, and complete blunting of the fornices.
VReflux into the and calyces with gross and of the , marked of the and calyces, and of the papillae with intrarenal .
These criteria emphasize progressive anatomical changes observed during VCUG, aiding in objective severity assessment. Clinically, the grading system guides management decisions by stratifying risk; low-grade VUR (I-II) often warrants due to high spontaneous resolution rates exceeding 80%, while high-grade VUR (IV-V) typically prompts closer monitoring or intervention given lower resolution rates (around 30-50%) and elevated risk of renal scarring (odds ratio 2.8 per patient for grades III-V). Higher grades correlate with increased likelihood of persistent reflux and complications like pyelonephritis-induced scarring, influencing choices between conservative observation and surgical options. Despite its utility, the system has limitations, including significant inter-observer variability, particularly for intermediate grades (II-IV), where agreement among radiologists can be as low as 50-70% due to subjective interpretations of and . Additionally, VUR grades are dynamic, potentially improving, worsening, or resolving over time with , which can alter initial classifications and necessitate serial imaging. The system relies on qualitative visual assessment without equation-based or quantitative scoring, limiting precision in borderline cases. In the 2020s, pediatric guidelines have refined VUR by reducing reliance on grading alone for low-risk cases, incorporating broader factors such as , breakthrough urinary tract infections, and dimercaptosuccinic acid ( results to prioritize individualized approaches over grade-specific protocols. For instance, the 2025 European Association of /European Society for Paediatric guidelines emphasize for low-grade or low-risk VUR without febrile recurrences, reflecting from trials like RIVUR that question universal prophylaxis.

Management

Conservative Approaches

Conservative management of vesicoureteral reflux (VUR) focuses on preventing urinary tract infections (UTIs) and monitoring for spontaneous resolution without invasive interventions, particularly in low-risk cases such as grades I-II or patients. This approach is supported by evidence showing high resolution rates for lower-grade VUR (up to 80% within 4-5 years) and aims to minimize exposure while preserving renal function. Antibiotic prophylaxis involves low-dose daily administration to reduce UTI recurrence in higher-risk children, such as those with grades III-V VUR or a history of febrile UTIs. agents include trimethoprim (2 mg/kg/day) or (1-2 mg/kg/day), selected based on local resistance patterns and patient age (e.g., avoiding in infants under 2 months). The RIVUR trial demonstrated that prophylaxis reduced recurrent UTI risk by 50% ( 0.50, 95% CI 0.34-0.74), with even greater efficacy in children with and bowel dysfunction (HR 0.21, 95% CI 0.08-0.58), though it increased the prevalence of antibiotic-resistant isolates. Guidelines recommend prophylaxis as a strong option for infants under 1 year with febrile UTI history or grades III-V VUR, but it is not routinely advised for low-grade (I-II) cases to avoid unnecessary resistance risks. Surveillance protocols emphasize periodic imaging to track VUR resolution and detect complications early, tailored to risk level. Renal and (RBUS) is performed every 6-12 months to assess growth and , while (VCUG) or radionuclide cystography follows at 12-24 month intervals or after breakthrough UTIs. For children with and bowel dysfunction (BBD), behavioral interventions such as timed voiding are integrated to improve emptying and reduce during . Dimercaptosuccinic acid (DMSA) scans are reserved for cases with abnormal , high-grade VUR, or febrile breakthrough infections to evaluate scarring. Lifestyle measures support conservative strategies by promoting optimal urinary tract health, especially in low-grade or VUR. is encouraged to dilute and flush potential pathogens, with children advised to sufficient fluids throughout the day. Double voiding—urinating again a few minutes after the initial void to ensure complete emptying—is recommended for cases with dysfunctional voiding to minimize residual and UTI susceptibility. These non-pharmacologic steps are particularly indicated for children over 1 year without BBD, complementing . Discontinuation of prophylaxis is guided by 2020s guidelines favoring selective use, considering factors like age, infection history, and VUR grade. Criteria include children over 5 years with no breakthrough infections for more than 1 year, evidence of grade improvement on imaging, or confirmed resolution via VCUG. Post-discontinuation, ongoing with and prompt evaluation of symptoms is advised to detect recurrences early. This risk-stratified approach balances benefits against concerns.

Interventional Treatments

Interventional treatments for vesicoureteral reflux (VUR) are indicated in cases of persistent reflux, breakthrough urinary tract infections despite , or high-grade disease with risk of renal damage. These approaches aim to correct the incompetent ureterovesical junction (UVJ) through minimally invasive or surgical means, with selection based on reflux grade, patient age, , and associated anomalies. Endoscopic injection therapy involves the subureteral injection of bulking agents, such as dextranomer/ (Dx/HA, e.g., Deflux), at the UVJ to achieve ureteral coaptation and prevent urine flow. This outpatient procedure is minimally invasive, performed cystoscopically under general , and is particularly suitable for grades I-III VUR or lower-risk patients. rates, defined as complete resolution on follow-up voiding cystourethrogram, range from 70% to 90% after a single injection for grades I-III, with diminishing efficacy for grades IV-V (typically 50-70%). Factors influencing include reflux , injection volume, and (e.g., hydrodistention implantation method improves outcomes). Repeat injections can achieve cumulative up to 85-90% in select cases. Surgical reimplantation, or ureteroneocystostomy, is the definitive treatment for high-grade (IV-V) or refractory VUR, offering durable correction through relocation of the ureteral orifice into the wall to create an anti-reflux mechanism. Intravesical approaches, such as the cross-trigonal technique (tunneling across the trigone) or Politano-Leadbetter method (intraluminal ureteral mobilization), are commonly used for bilateral cases, while extravesical techniques like Lich-Gregoir ( tunneling outside the ) avoid bladder opening and reduce postoperative voiding issues, ideal for unilateral reflux. Open surgery achieves success rates exceeding 95%, with resolution in over 97% of renal units regardless of grade. These procedures are typically inpatient, with hospital stays of 1-3 days, and are recommended by guidelines for persistent febrile infections or progressive scarring. Advances in minimally invasive , including robotic-assisted laparoscopic ureteral reimplantation (RALUR), have emerged in the as alternatives to open techniques, particularly for bilateral or secondary VUR. RALUR employs robotic systems for precise extravesical or intravesical reimplantation, reducing incision size, loss, and time (often within 24-48 hours) compared to open . Success rates are comparable to open approaches (85-96%), with lower analgesia needs and faster return to activities, though longer operative times (3-5 hours). These methods are indicated for complex cases but require specialized centers due to equipment demands. Overall outcomes emphasize reflux resolution tailored to disease severity: endoscopic options for lower grades to avoid surgery, and reimplantation for high-risk cases to prevent complications like pyelonephritis. Risks include rare ureteral obstruction (<1% for endoscopic, 1-5% for surgical), postoperative urinary tract infections (up to 5%), and transient voiding dysfunction (2-4%), with most managed conservatively via stenting or antibiotics. Long-term follow-up with imaging is essential to monitor resolution and renal function.

Epidemiology

Prevalence and Incidence

Vesicoureteral reflux (VUR) has an estimated overall of 1% to 2% among children in the general population. In unselected newborns, the incidence is approximately 1%, though this may be underestimated due to the need for invasive diagnostic procedures like (VCUG). The condition is detected much more frequently in specific subgroups, such as children presenting with urinary tract infections (UTIs), where ranges from 30% to 40%. For instance, among infants with febrile UTIs, VUR is identified in up to 51% of cases, highlighting its association with symptomatic presentations. Prevalence peaks during infancy, with higher rates observed in neonates screened for prenatal hydronephrosis, where VUR is found in about 15% to 16% of cases. Spontaneous resolution is common, occurring in 70% to 80% of low-grade (I-II) cases by age 5 years, and overall, up to 80% of primary VUR resolves by through natural maturation of the ureterovesical junction. In contrast, the prevalence of VUR in the general adult population is low and not well defined, with most persistent cases being secondary to underlying conditions like outlet obstruction rather than primary congenital VUR. Global variations in detection rates are influenced by screening practices, with higher reported in populations routinely evaluated post-UTI or via familial screening, such as 27% to 36% among siblings of affected children. Large cohort studies and reviews from the to 2020s, including meta-analyses of pediatric UTI populations, confirm consistently elevated rates in screened groups compared to unscreened cohorts. The widespread use of prenatal has significantly increased early diagnosis rates, identifying VUR in 15% to 30% of fetuses with antenatal and enabling proactive management to mitigate renal risks.

Demographic Patterns

Vesicoureteral reflux (VUR) exhibits notable disparities, with an overall approximately twice as high in females as in males among children evaluated for urinary tract infections (UTIs). This pattern is attributed in part to the higher incidence of UTIs in females due to anatomical factors such as the shorter , which increases the likelihood of VUR detection during routine evaluations. However, in infants, particularly those identified through prenatal , VUR is more common in males, with studies reporting up to 75% male predominance in this age group. In adults, primary VUR is rare without secondary causes and shows a more balanced distribution, often persisting only in cases associated with underlying conditions like neurogenic . Age-related patterns reveal that VUR is most frequently diagnosed in , with spontaneous resolution common before age 5, though high-grade cases rarely resolve beyond this point. Ethnically, VUR occurs three times more frequently in children compared to children, with girls facing up to a 10-fold higher risk than their African-American counterparts; this disparity may reflect genetic factors or differences in screening practices. Familial aggregation affects 25-30% of first-degree relatives, following an autosomal dominant inheritance pattern with incomplete , leading to recommendations for screening siblings where incidence reaches 27-46%. Primary VUR is uncommon in adults absent secondary etiologies, underscoring its predominantly pediatric nature. Geographic and epidemiologic variations influence VUR detection, with higher reported incidence in regions employing routine UTI screening protocols, such as in certain high-income countries where imaging is standard post-infection. Socioeconomic barriers, including limited access to healthcare, contribute to delayed and underreporting in underserved populations, exacerbating outcomes through untreated recurrent UTIs. VUR shows syndromic associations, occurring in 10-20% of children with congenital anomalies of the and urinary tract (CAKUT), where it often coexists with conditions like ureteropelvic obstruction or duplex systems, heightening risks for renal impairment.

History

Early Recognition

The earliest clinical observation of vesicoureteral reflux (VUR) dates to 1893, when Pozzi noted retrograde urine flow from the severed distal during a procedure, marking the first documented instance in humans. This incidental finding highlighted the potential for abnormal urine backflow but lacked broader clinical context at the time. In the late 19th and early 20th centuries, such observations remained rare, often confined to surgical or autopsy settings, with limited of VUR as a distinct entity. By the early 1900s, advancements in enabled more direct visualization of . In 1913, French urologists Georges Legueu and Étienne Papin reported a case of bilateral and hydroureter in which urine clearly refluxed through a widely patent ureteral orifice during examination, associating the condition with upper urinary tract dilation. Similarly, in 1914, American urologist Howard Kretschmer used early to demonstrate in 4 out of 11 children studied, further linking it to urinary . These cystoscopic insights began to differentiate VUR from simple obstruction, though diagnostic capabilities were rudimentary without routine imaging. In the pre-imaging era, VUR was primarily identified through clinical associations with recurrent urinary tract infections and renal dilation, particularly in children, where it was frequently regarded as an idiopathic contributor to or treated symptomatically without targeted intervention. German pathologist Carl Maximilian Gruber, in , observed that reflux prevalence correlated with shorter intravesical ureter lengths and reduced detrusor backing, providing an early anatomical framework for its occurrence during voiding. This period saw initial informal distinctions between primary (congenital, intrinsic ureterovesical junction defects) and secondary (acquired, due to outlet obstruction or neurogenic ) forms via cystoscopic evaluation, though formal classifications awaited later developments. Key contributions in the mid-20th century solidified early understanding. In 1952, American urologist John A. Hutch described VUR in clinical studies of paraplegic patients, linking it directly to and renal scarring as a consequence of , and proposing saccule formation at the ureterovesical junction as a predisposing factor. Hutch's work emphasized VUR's role in progressive damage from recurrent infections, shifting perceptions from mere anatomical curiosity to a clinically significant condition. Building on this, in the , British pediatric urologist David Innes Williams advanced the congenital basis of primary VUR in children, detailing its association with ureteral ectopia and recurrent infections through clinical observations and cystographic studies.

Key Advancements

The introduction of (VCUG) in 1947 revolutionized the of vesicoureteral reflux (VUR) by enabling direct visualization of retrograde urine flow from the bladder into the ureters and renal pelvis during micturition. In the 1970s, technetium-99m dimercaptosuccinic acid (DMSA) emerged as a key tool for detecting renal parenchymal scarring associated with VUR, providing functional assessment of cortical defects that correlated with prior episodes. The 1985 International Reflux Study in Children established a standardized five-grade classification system based on VCUG findings, which graded reflux severity by the extent of ureteral dilation, pelvic involvement, and calyceal tortuosity, facilitating consistent prognostic and therapeutic decisions worldwide. Treatment paradigms shifted in the 1960s with the widespread adoption of ureteral reimplantation , particularly the Politano-Leadbetter intravesical technique introduced in , which achieved high success rates (over 95%) in correcting by creating an anti- submucosal tunnel. By the 1990s, large-scale trials from the International Reflux Study demonstrated the efficacy of continuous antibiotic prophylaxis in reducing recurrent urinary tract infections (UTIs), prompting a move away from routine toward for lower-grade . Endoscopic injection of dextranomer/ (Deflux) gained FDA approval in 2001 as a minimally invasive alternative, offering 70-85% resolution rates for grades II-IV VUR with reduced morbidity compared to open . In the 2010s, robotic-assisted laparoscopic ureteral reimplantation emerged, with initial series from 2007-2010 reporting success rates of 85-95% and shorter hospital stays, enhancing precision in pediatric cases. Key research advancements include the 2014 Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial, a multicenter randomized controlled study of 607 children that found daily trimethoprim-sulfamethoxazole prophylaxis reduced UTI recurrence by 50% in grades I-IV VUR but did not significantly prevent renal scarring. Genetic studies in the identified heterozygous mutations in the ROBO2 gene as contributors to familial VUR, linking disruptions in slit/robo signaling pathways to ureteral budding defects and affecting up to 10% of primary cases. Recent 2020s guidelines, such as the 2024 European Association of Urology updates, emphasize risk stratification to reduce overtreatment, recommending against routine imaging or prophylaxis in low-risk infants and prioritizing shared decision-making to minimize unnecessary interventions. Prognostic understanding evolved with recognition of high spontaneous rates, particularly for low- VUR, where studies from the 1970s onward reported annual of 20-30% in I-III, driven by growth of the intramural and influenced by initial , at , and . This insight shifted management from aggressive surgical correction to expectant observation with surveillance, balancing UTI prevention against risks of resistance and procedural complications.

References

  1. [1]
    Vesicoureteral Reflux (VUR) - NIDDK
    Vesicoureteral reflux (VUR) is a condition in which urine flows backward from the bladder to one or both ureters and sometimes to the kidneys.What are the symptoms and... · How do doctors diagnose...
  2. [2]
    Vesicoureteral reflux - Symptoms and causes - Mayo Clinic
    Feb 5, 2025 · Vesicoureteral (ves-ih-koe-yoo-REE-tur-ul) reflux means that some urine flows in the wrong direction once it reaches the bladder.
  3. [3]
    Vesicoureteral Reflux (VUR) - Johns Hopkins Medicine
    Vesicoureteral reflux happens when urine dwelling in the bladder flows back into the ureters and often back into the kidneys.Missing: definition | Show results with:definition
  4. [4]
    Vesicoureteral Reflux - StatPearls - NCBI Bookshelf
    Vesicoureteral reflux (VUR) is characterized by the abnormal backward flow of urine from the urinary bladder into the upper urinary tract during voiding.
  5. [5]
    Vesicoureteral Reflux: Practice Essentials, Background, Relevant ...
    Sep 30, 2021 · Vesicoureteral reflux (VUR) is defined as retrograde regurgitation of urine from the urinary bladder up the ureter and into the collecting system of the ...
  6. [6]
    Vesicoureteral Reflux and Reflux Nephropathy - PMC - NIH
    VUR-related renal scarring is more common with UTI and the odds ratio of renal scarring with acute pyelonephritis in the presence of a VUR is 2.8 for patients ...
  7. [7]
    Vesicoureteral Reflux (VUR) - Pediatrics - MSD Manuals
    Pathophysiology of VUR​​ Reflux of urine from the bladder into the ureter may damage the upper urinary tract by bacterial infection and occasionally by increased ...
  8. [8]
    Embryology and genetics of primary vesico-ureteric reflux and ...
    Primary vesico-ureteric reflux (VUR) is a congenital defect of the urinary tract that causes urine to flow retrogradely from the bladder to the kidneys and it ...
  9. [9]
    Genetics of Vesicoureteral Reflux - PMC - NIH
    Primary VUR is a congenital condition caused by the abnormal development and malfunction of the ureterovesical junction (UVJ). By contrast, secondary VUR is an ...
  10. [10]
    ROBO2 Gene Variants Are Associated with Familial Vesicoureteral ...
    In conclusion, our study independently confirms that genetic alterations in ROBO2 are significantly associated with familial VUR/CAKUT. Furthermore, we showed ...Robo2 Gene Variants Are... · Results · Robo2 Sequence Analysis
  11. [11]
    Vesicoureteral Reflux - PubMed
    Apr 30, 2024 · However, early diagnosis and timely treatment of VUR can prevent renal damage and recurrent UTIs and salvage the kidneys. Bladder or bowel ...
  12. [12]
    Primary Vesicoureteral Reflux and Renal Scarring - PubMed
    High-grade VUR, recurrent pyelonephritis, and delayed initiation of antibiotic treatment are important risk factors for renal scarring.
  13. [13]
    Reflux Nephropathy - StatPearls - NCBI Bookshelf
    Reflux nephropathy is a direct consequence of VUR or other urologic congenital anomalies stemming from chronic high-pressure sterile urine reflux and often ...
  14. [14]
    Vesicoureteral reflux is associated with increased risk of chronic ...
    Aug 25, 2023 · For many years, VUR has been considered a risk factor for UTI, acute pyelonephritis, and renal parenchymal damage but whether children VUR ...Missing: recurrent | Show results with:recurrent
  15. [15]
    Vesicoureteral Reflux, a Scarred kidney, and Minimal Proteinuria - NIH
    Primary VUR occurs in the absence of any underlying pathology, while secondary VUR in the adult occurs due to conditions such as obstruction, previous surgical ...
  16. [16]
    Reflux nephropathy and chronic atrophic pyelonephritis: a review
    Proteinuria is the worst prognostic feature in patients with reflux nephropathy and pyelonephritic scarring. Intrarenal reflux determines the site of scarring.Missing: vesicoureteral recurrent
  17. [17]
    Effect of vesicoureteric reflux on renal growth in children with urinary ...
    A significant association was found between impaired growth and, independently, infection and renal scarring. No independent association was found between ...Missing: vesicoureteral | Show results with:vesicoureteral
  18. [18]
    Vesicoureteral Reflux Guideline - American Urological Association
    Surgical treatment of VUR​​ The resolution rate per 100 children was 98.1 for open surgery (95% CI: 95.1, 99.1) and 83.0 for endoscopic therapy (95% CI: 69.1, 91 ...
  19. [19]
    EAU Guidelines on Paediatric Urology - Uroweb
    In this chapter we highlight normal development, its variations and how to discern this from abnormal foreskin requiring treatment, as well as various ...
  20. [20]
    Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis ...
    VCUG should not be performed routinely after the first febrile UTI; VCUG is indicated if RBUS reveals hydronephrosis, scarring, or other findings that would ...This Clinical Practice... · INTRODUCTION · Culture · AREAS FOR RESEARCH
  21. [21]
    International system of radiographic grading of vesicoureteric reflux ...
    The classification of grading of vesicoureteric reflux (VUR) agreed to by the participants in the International Reflux Study in Children is described.
  22. [22]
    Vesicoureteric reflux (grading) | Radiology Reference Article
    Oct 1, 2025 · grade 1: reflux limited to the ureter · grade 2: reflux up to the renal pelvis · grade 3: mild dilatation of ureter and pelvicalyceal system.
  23. [23]
    Pediatric Vesicoureteral Reflux Treatment & Management
    May 28, 2024 · In general, however, low-grade VUR (grades I-II) has high rates of spontaneous resolution (usually >80%). High-grade VUR, especially grade V ...
  24. [24]
    Reliability of grading of vesicoureteral reflux and other findings ... - NIH
    Sep 6, 2016 · There is considerable inter-observer variability for grading VUR. This has both research and clinical implications, as study design, risk ...
  25. [25]
    [PDF] EAU Guidelines on Paediatric Urology - Cloudfront.net
    allows grading of VUR [919]. In 1985, the International Reflux Study Committee introduced a uniform system for the classification of VUR [920, 921] (Table 2).Missing: reliance | Show results with:reliance
  26. [26]
    Update and Summary of the European Association of Urology ...
    Jan 5, 2024 · The aim of these guidelines is to provide a practical approach to the treatment of VUR that is based on risk analysis and selective indications ...Missing: 2020s reducing reliance
  27. [27]
    Vesicoureteral Reflux Topics - American Urological Association
    Recommendation: Continuous antibiotic prophylaxis is recommended for the child with bladder/bowel dysfunction and VUR due to the increased risk of urinary ...
  28. [28]
    [PDF] EAU guidelines on paediatric urology - Cloudfront.net
    conservative management to monitor spontaneous resolution and kidney status. Vesicoureteral reflux increases the risk of febrile UTI and renal scarring ...
  29. [29]
    Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux
    May 4, 2014 · Prophylaxis reduced the risk of recurrences by 50% (hazard ratio, 0.50; 95% CI, 0.34 to 0.74) and was particularly effective in children whose ...
  30. [30]
    Vesicoureteral reflux - Diagnosis and treatment - Mayo Clinic
    Feb 5, 2025 · Kidney and bladder ultrasound.​​ It also may reveal swollen kidneys in the baby. That can be a symptom of primary vesicoureteral reflux.
  31. [31]
    Vesicoureteral reflux (VUR): symptoms, diagnosis and treatments
    Vesico-ureteric reflux (VUR) is a condition in which urine travels back up the tubes connecting the kidneys to the bladder (known as the ureters) towards ...Missing: definition | Show results with:definition
  32. [32]
    A systematic review of outcomes of Deflux® treatment for ... - PubMed
    The mean success rate was 36.8%. Ureteral obstruction occurred in 7/67 cases (10.4%). In all these 7 cases of obstruction, ureteric stenting was the initial ...
  33. [33]
    Subureteral injection of Deflux for correction of reflux - PubMed
    Results: The success rate by grade of reflux in individual ureters was 82%, 84%, 78%, and 73% for grade 1, 2, 3, and 4 vesicoureteral reflux, respectively.
  34. [34]
    Factors affecting the success of endoscopic treatment of ... - PubMed
    Mar 2, 2015 · The overall success rate was 73.2%. ... The postoperative UTI (5 febrile and 43 nonfebrile) rate was 20%. Both univariate and multivariate ...
  35. [35]
    Treatment of vesicoureteral reflux in adults by endoscopic injection
    Apr 15, 2011 · Results: VUR was corrected in 38 (93%) of 41 ureteral units. Of the 3 failures, 1 patient had a large Hutch diverticulum and another had ...
  36. [36]
    Comparison of intravesical (Cohen) and extravesical (Lich-Gregoir ...
    The success rate of the two groups were comparable (100% vs 94.9%, p = 0.513). No intraoperative complications were detected in either group. The number of ...
  37. [37]
    Vesicoureteral reflux after ureteroneocystostomy - PubMed
    Reflux resolution rates for 534 renal units and 273 patients after routine follow-up voiding cystourethrogram (VCUG) was 97.8% (renal units) and 96% (patients), ...
  38. [38]
    A Systematic Review of Outcomes of Redo Ureteroneocystostomy ...
    Jun 9, 2025 · The intravesical approach, most commonly the Cohen technique, was used in 14 patients. The average success rate for redo UNC was 91.4%.
  39. [39]
    Robot-assisted laparoscopic extravesical ureteral reimplantation ...
    Sep 30, 2024 · The mean age at the procedure was 6 years, and the mean follow-up length was 20.4 months. The overall success rate of surgery was 92.2% for ...
  40. [40]
    A multi-institutional European comparative study of open ... - PubMed
    Robotic-assisted laparoscopic ureteral reimplantation (RALUR) is gaining popularity and high success rates have been reported. Objective: In this multi- ...
  41. [41]
    The LUAA Gundeti Technique for Bilateral Robotic Ureteral ...
    Sep 28, 2023 · Results and limitations: The overall radiographic resolution rate was 85.2%, with success rates of 76.7%, 75%, and 96.7% across the three ...
  42. [42]
    trends and outcomes in a NSQIP-P cohort - PubMed
    Jul 8, 2022 · Success rates with MIS are similar to open for re-implantation (> 90%); however, open ureteral re-implantation is still widely considered the ...Missing: reimplantation | Show results with:reimplantation
  43. [43]
    Antibiotic prophylaxis in vesicoureteral reflux: A practice revisited - NIH
    The 1997 guidelines of the American Urological Association (AUA) recommended that CAP be used to manage children younger than 10 years with grades I to IV VUR.
  44. [44]
    Vesicoureteral Reflux in Children with Urinary Tract Infections ... - NIH
    Mar 12, 2022 · In the current study, the UTI children with VUR were associated with increased risks of small kidneys and progression to ESRD.
  45. [45]
    Has the Data Efflux Regarding the Promising Outcome Following ...
    Mar 10, 2009 · 2. Prevalence of VUR in Adults. In the general pediatric population, the prevalence of VUR is around 1-2% with higher rates in siblings (30%) ...
  46. [46]
  47. [47]
    Outcome of Vesicoureteral Reflux in Infants: Impact of Prenatal ... - NIH
    The advent of prenatal ultrasonography has enhanced the early detection of various urinary tract abnormalities such as VUR. Reflux was detected in 15-30% of ...
  48. [48]
    Incidence and severity of vesicoureteral reflux in children ... - PubMed
    The incidence of VUR in black girls younger than 7 years with a diagnosis of UTI was less than 10% compared to white girls, and no black girl had high grade ...
  49. [49]
    Primary Vesico-Ureteral Reflux: Comparison of Factors ... - PubMed
    Mar 18, 2011 · Our data showed that VUR in infant was significantly higher in male than in female, whereas VUR in children was significantly higher in ...
  50. [50]
    [Vesicoureteral reflux in adults] - PubMed
    Primary VUR is due to a defect in the valve mechanism of the ureterovesical junction. In physiological conditions, the terminal ureter enters the bladder ...
  51. [51]
    The frequency of vesicoureteral reflux diagnosis is correlated with ...
    The occurrence rate of VUR in the pediatric population ranged from 2.63 in 1998 to 3.94 in 2003 per 10,000 children during 1998-2005. The frequency of newly ...Missing: prevalence incidence<|control11|><|separator|>
  52. [52]
    Delayed diagnosis of primary vesicoureteral reflux in children with ...
    May 31, 2018 · Low socioeconomic status of patients, their parents' and healthcare personnel's insufficient awareness of urinary tract infection (UTI) and ...
  53. [53]
    Update on Vesicoureteral Reflux: Pathogenesis, Nephropathy ... - NIH
    Clinical reflux was first visualized over 100 years ago in 1893 when Pozzi observed reflux ... vesicoureteral reflux has evolved through many stages. The ...
  54. [54]
    Vesicoureteral Reflux: Where Have We Been, Where Are We Now ...
    Aug 11, 2008 · Reflux was recognized very early, as an abnormal function of the ureterovesical junction, but it was Hutch who recognized it in association ...
  55. [55]
    Vesico-ureteral reflux in the paraplegic: cause and correction. 1952
    Vesico-ureteral reflux in the paraplegic: cause and correction. 1952. ... Vesico-Ureteral Reflux / history*. Personal name as subject. John A Hutch.Missing: early recognition Simon 1872
  56. [56]
    History of Pediatric Urologic Imaging - Radiology Key
    Aug 11, 2016 · In the early to mid-1960s, VCUG became more accepted as a major diagnostic tool in pediatric uroradiology. Today VCUG is the principal ...
  57. [57]
    Particularities in the “Oldie but Goldie” Tc-99m DMSA Renography
    Apr 17, 2025 · The Tc-99m DMSA scan is a non-invasive technique that provides accurate structural and functional information about kidney malformations and ...
  58. [58]
    Vesicoureteral reflux: A historical perspective - ScienceDirect.com
    The purpose of this article is to provide the reader with a historical perspective on management and delineate how its past has shaped current therapies and ...
  59. [59]
    UNILATERAL EXTRAVESICAL URETERAL REIMPLANTATION IN ...
    Ureteral reimplantation is an accepted method of surgical therapy for vesicoureteral reflux (VUR), with a durable success rate of more than 90%.
  60. [60]
    Premarket Approval (PMA) - FDA
    Approval Order Statement APPROVAL FOR DEFLUX INJECTABLE GEL. THE DEVICE IS INDICATED FOR TREATMENT OF CHILDREN WITH VESICOURETERAL REFLUX (VUR) GRADES II-IV.
  61. [61]
    Lessons learned over a decade of pediatric robotic ureteral ... - NIH
    Jan 9, 2017 · Robot-assisted laparoscopic ureteral reimplantation (RALUR) has become a viable minimally invasive surgical option for pediatric vesicoureteral reflux (VUR).
  62. [62]
    Antimicrobial prophylaxis for children with vesicoureteral reflux
    Jun 19, 2014 · Prophylaxis reduced the risk of recurrences by 50% (hazard ratio, 0.50; 95% CI, 0.34 to 0.74) and was particularly effective in children whose ...
  63. [63]
    Management of Vesicoureteral Reflux: What Have We Learned Over ...
    Endoscopic treatment is recommended principally as an option for children with low grades of VUR (up to grade III) and, for high-risk patients with renal ...Missing: 2020s | Show results with:2020s